Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2017

View Archived Issues

GSK to incorporate Owlstone's Breath Biopsy platform into danirixin clinical program

Bicycle Therapeutics creates novel peptide-toxin conjugates specific for MT1-MMP

aTyr Pharma initiates dosing in first-in-human trial of iMod.Fc

Novel HIV integrase inhibitors discovered at ViiV Healthcare

Sunshine Lake Pharma patents novel memantine prodrugs

Catalyst Pharmaceuticals reports topline results from phase III study of Firdapse

Kyowa Hakko Kirin licenses tenapanor rights in Japan from Ardelyx

FDA grants priority review to Dova's NDA for avatrombopag

Otonomy discontinues commercial support for Otiprio, focuses resources on otology pipeline

EMA accepts Macrilen MAA for adult growth hormone deficiency

Biogen and Alkermes collaborate to develop and commercialize ALKS-8700 for MS

VE-2851, a promising novel thrombin inhibitor with low bleeding risk

FDA grants fast track designation to Stealth Biotherapeutics' elamipretide

Medeor Therapeutics closes series B financing

Prima BioMed changes name to Immutep

EMA accepts Tagrisso submission in first-line EGFR-mutated NSCLC

KY-1044 elicits long-term in vivo antitumor efficacy

AbbVie announces launch of Maviret in Japan

Eureka Therapeutics cleared by FDA for phase I study of ET-190L1-Artemis T cells

In vitro and in vivo characterization of the novel anti-CTLA-4 antibody ADU-1604

Long-lasting neutralizing antibody responses seen with dengue vaccine KD-382 in cynomolgus monkeys

Novel gene variations linked to common forms of epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...